Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3RSMF)

• Drug Name: SGX523 Drug Info
• Synonyms: SGX-523; SGX523, SGX-523

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 24779724
  ChEBI ID: CHEBI:90624
  CAS Number: CAS 1022150-57-7
  TTD Drug ID: DM3RSMF
  INTEDE Drug ID: DR1802

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[5]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[6]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[7]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[8]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[9]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[10]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[11]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[12]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[9]

Drug(s) Metabolized By Aldehyde oxidase (AOX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zaleplon	DMGFWSM	Insomnia	7A00-7A0Z	Approved	[13]
XL147	DMML7BE	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
VUFB-11502	DM7WFR0	N. A.	N. A.	Preclinical	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Aldehyde oxidase (AOX1) Main DME	DEAWHS8	AOXA_HUMAN	Substrate	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5709).
• [2] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [3] Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos. 2010 Aug;38(8):1277-85.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Clinical pipeline report, company report or official report of Exelixis (2011).
• [6] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [13] Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos. 2012 Feb;40(2):267-75.
• [14] The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.